Banyu To Sell Facility To Taiho, Move All Research To U.S.
This article was originally published in PharmAsia News
Executive Summary
Japan's Banyu Pharmaceutical plans to sell its research facility to Taiho Pharmaceutical, with the deal to be completed by the end of August. Banyu, a subsidiary of U.S.-based Merck, is moving its research work to the United States and assigning its employees at the Japanese facility to other divisions. The Banyu change is part of a global restructuring by Merck. For Taiho, the facility is to serve as its base for developing the cancer drugs in which it specializes. (Click here for more - a subscription may be required